Cargando…
Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
Photoactivatable Pt(IV) anticancer prodrugs with the structure of [Pt(IV)(N(1))(N(2))(L(1))(L(2))(A(1))(A(2))], where N(1) and N(2) are non-leaving nitrogen donor ligands, L(1) and L(2) are leaving ligands, and A(1) and A(2) are axial ligands, have attracted increasing attention due to their promisi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218644/ https://www.ncbi.nlm.nih.gov/pubmed/35755267 http://dx.doi.org/10.3389/fchem.2022.876410 |
_version_ | 1784731934532829184 |
---|---|
author | Huang, Jingjing Ding, Weize Zhu, Xingfan Li, Bingbing Zeng, Fangang Wu, Kui Wu, Xiaoqin Wang, Fuyi |
author_facet | Huang, Jingjing Ding, Weize Zhu, Xingfan Li, Bingbing Zeng, Fangang Wu, Kui Wu, Xiaoqin Wang, Fuyi |
author_sort | Huang, Jingjing |
collection | PubMed |
description | Photoactivatable Pt(IV) anticancer prodrugs with the structure of [Pt(IV)(N(1))(N(2))(L(1))(L(2))(A(1))(A(2))], where N(1) and N(2) are non-leaving nitrogen donor ligands, L(1) and L(2) are leaving ligands, and A(1) and A(2) are axial ligands, have attracted increasing attention due to their promising photo-cytotoxicity even to cisplatin-resistant cancer cells. These photochemotherapeutic prodrugs have high dark-stability under physiological conditions, while they can be activated by visible light restrained at the disease areas, as a consequence showing higher spatial and temporal controllability and much more safety than conventional chemotherapy. The coordinated ligands to the Pt center have been proved to be pivotal in determining the function and activity of the photoactivatable Pt(IV) prodrugs. In this review, we will focus on the development of the coordinated ligands in such Pt(IV) prodrugs and discuss the effects of diverse ligands on their photochemistry and photoactivity as well as the future evolution directions of the ligands. We hope this review can help to facilitate the design and development of novel photoactivatable Pt(IV) anticancer prodrugs. |
format | Online Article Text |
id | pubmed-9218644 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92186442022-06-24 Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs Huang, Jingjing Ding, Weize Zhu, Xingfan Li, Bingbing Zeng, Fangang Wu, Kui Wu, Xiaoqin Wang, Fuyi Front Chem Chemistry Photoactivatable Pt(IV) anticancer prodrugs with the structure of [Pt(IV)(N(1))(N(2))(L(1))(L(2))(A(1))(A(2))], where N(1) and N(2) are non-leaving nitrogen donor ligands, L(1) and L(2) are leaving ligands, and A(1) and A(2) are axial ligands, have attracted increasing attention due to their promising photo-cytotoxicity even to cisplatin-resistant cancer cells. These photochemotherapeutic prodrugs have high dark-stability under physiological conditions, while they can be activated by visible light restrained at the disease areas, as a consequence showing higher spatial and temporal controllability and much more safety than conventional chemotherapy. The coordinated ligands to the Pt center have been proved to be pivotal in determining the function and activity of the photoactivatable Pt(IV) prodrugs. In this review, we will focus on the development of the coordinated ligands in such Pt(IV) prodrugs and discuss the effects of diverse ligands on their photochemistry and photoactivity as well as the future evolution directions of the ligands. We hope this review can help to facilitate the design and development of novel photoactivatable Pt(IV) anticancer prodrugs. Frontiers Media S.A. 2022-06-09 /pmc/articles/PMC9218644/ /pubmed/35755267 http://dx.doi.org/10.3389/fchem.2022.876410 Text en Copyright © 2022 Huang, Ding, Zhu, Li, Zeng, Wu, Wu and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Chemistry Huang, Jingjing Ding, Weize Zhu, Xingfan Li, Bingbing Zeng, Fangang Wu, Kui Wu, Xiaoqin Wang, Fuyi Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs |
title | Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs |
title_full | Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs |
title_fullStr | Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs |
title_full_unstemmed | Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs |
title_short | Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs |
title_sort | ligand evolution in the photoactivatable platinum(iv) anticancer prodrugs |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218644/ https://www.ncbi.nlm.nih.gov/pubmed/35755267 http://dx.doi.org/10.3389/fchem.2022.876410 |
work_keys_str_mv | AT huangjingjing ligandevolutioninthephotoactivatableplatinumivanticancerprodrugs AT dingweize ligandevolutioninthephotoactivatableplatinumivanticancerprodrugs AT zhuxingfan ligandevolutioninthephotoactivatableplatinumivanticancerprodrugs AT libingbing ligandevolutioninthephotoactivatableplatinumivanticancerprodrugs AT zengfangang ligandevolutioninthephotoactivatableplatinumivanticancerprodrugs AT wukui ligandevolutioninthephotoactivatableplatinumivanticancerprodrugs AT wuxiaoqin ligandevolutioninthephotoactivatableplatinumivanticancerprodrugs AT wangfuyi ligandevolutioninthephotoactivatableplatinumivanticancerprodrugs |